News

Hosted on MSN4mon
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...
The American Journal of Managed Care4mon
Esketamine Approved by FDA as First Monotherapy for Treatment-Resistent Depression
Esketamine is the first monotherapy for MDD with inadequate response to two oral antidepressants, approved after a priority FDA review. Clinical trials showed esketamine's rapid efficacy, with 22. ...
Yahoo Finance10mon
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
Johnson & Johnson Innovative Medicine. "We're pleased to build on the more than a decade of research reinforcing the safety and efficacy of SPRAVATO ® and look forward to working with the FDA to ...
Monthly Prescribing Reference10mon
J&J Submits sNDA for Spravato as Monotherapy in Treatment-Resistant Depression
Esketamine monotherapy was found to significantly improve depressive symptoms in patients with treatment-resistant depression. Johnson & Johnson is seeking to expand the approval of Spravato ...
USA Today3mon
FDA approved nasal spray, known as esketamine, to treat major depression is biggest advance in years
On Tuesday, the government agency announced Spravato nasal spray, also known as esketamine ... to Janssen Pharmaceutical Companies of Johnson & Johnson, which developed Spravato.
NPR4mon
FDA allows standalone use of nasal spray antidepressant Spravato (esketamine)
Spravato is made from esketamine, one of two mirror-image molecules ... the drug generated sales of about $780 million for its maker, Johnson & Johnson. Spravato is intended to be administered ...
Yahoo Finance4mon
SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression
TITUSVILLE, N.J., Jan. 21, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for ...
The Victoria Advocate10mon
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
TITUSVILLE, N.J., July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE ... seeking approval of SPRAVATO ® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment ...
Finanznachrichten10mon
Johnson & Johnson seeks U.S. FDA approval of SPRAVATO (esketamine) as the first and only monotherapy for adults with treatment-resistant depression
2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ...